A novel in vitro whole blood model was developed to study human antimycobacterial immunity. Recombinant reporter mycobacteria were used to enumerate the bacteria, and interactions between host immune cells and mycobacteria were studied using whole blood rather than cell fractions. The ability of healthy tuberculin-positive and tuberculin-negative individuals to restrict mycobacterial growth was compared. Growth of luminescent mycobacteria was significantly lower in blood samples of tuberculin-positive individuals than in blood samples of tuberculin-negative individuals ( ). Restricted mycobacterial growth P p .005 was associated with significantly higher production of tumor necrosis factor (TNF)-a and interferon (IFN)-g ( and .004, respectively). Inhibition of the TNF-a and IFN-g re-P p .01 sponse pathways by neutralizing monoclonal antibodies increased mycobacterial growth in whole blood. This model is the first functional assay in which individual variations in cellmediated immunity are shown to correlate with differences in ability to control mycobacterial growth. It provides a new tool for studying human mycobactericidal mechanisms and, potentially, for the evaluation of improved vaccines.
development of improved vaccines is the inadequate understanding of the mechanisms underlying protective immunity. Most individuals infected with M. tuberculosis or vaccinated with BCG develop an immune response that can be detected in the form of a delayed-type hypersensitivity reaction to intradermal injection of a crude mixture of M. tuberculosis antigens (tuberculin). Although the tuberculin response provides evidence of previous exposure to mycobacteria, it does not distinguish individuals who will go on to develop progressive disease from those who can successfully contain the infection [6] . Improved understanding of the mechanisms responsible for containing mycobacterial growth in humans is essential for the development of improved vaccines [7] .
Immunity to mycobacterial infection has been studied extensively in mice, but the extent to which these observations can be extrapolated to humans is unclear. Murine macrophages are able to restrict the growth of mycobacteria in vitro by a pathway that depends on generation of reactive nitrogen intermediates [8, 9] and is enhanced by the addition of interferon (IFN)-g [10, 11] and tumor necrosis factor (TNF)-a [12] and by the presence of interleukin (IL)-12 [13] . Multiple subsets of T cells are essential for protective immunity in mice [14, 15] , but no single immune activity is, in itself, sufficient to confer optimal protection.
The increased susceptibility to mycobacterial infections in humans with mutations that affect the IFN-g receptor [16, 17] and the IL-12 receptor [18] emphasizes the crucial role these pathways play in humans as well. Conflicting data on the role of T cells [19] , macrophages [20] , and immune effector mechanisms [21] in the human host have been published, and it is likely that a complex interaction of cellular and humoral factors Downloaded from https://academic.oup.com/jid/article-abstract/182/3/895/873934 by guest on 22 February 2019 [22] is required to contain the growth of mycobacteria [23] . However, there is general agreement that the ultimate factor determining immunity is the ability of the human immune system to prevent growth of intracellular mycobacteria within the target cell population-that is, the macrophage.
The mechanisms involved in restriction of mycobacterial growth have been difficult to study because of the slow growth of the organism; 2-4 weeks are required for formation of colonies according to conventional culture protocols. Expression of recombinant luciferase enzymes has been widely used as a reporter, to monitor changes in cell viability in bacterial and eucaryotic systems. In mycobacteria, luciferase reporters have been used mainly to monitor the effect of drugs on viability [24] , but they have also shown some promise in detecting immune-mediated killing in animal models [25, 26] . We postulated that the reporter gene strategy could be used to study human mycobactericidal mechanisms in whole human blood, which contains all the cellular and humoral components potentially required for control of mycobacterial growth.
Materials and Methods
Human subjects. Response to 10 U of purified protein derivative (PPD; tuberculin PPD 100 U/mL; Evans Medical Ltd., Leatherhead, UK) was assessed in 20 healthy adult volunteers 3-6 months prior to collection of blood samples. Groups of 10 tuberculin-negative individuals with an induration !5 mm and 10 tuberculin-positive individuals with an induration 115 mm were recruited for the study. Peripheral blood obtained by venipuncture was diluted with an equal volume of RPMI 1640 (Life Technologies Ltd., Paisley, UK), supplemented with 1% L-glutamine and heparin (10 U/mL; Monoparin 1000 U/mL; CP Pharmaceuticals Ltd., Wrexham, UK). Part of the blood sample was centrifuged for 10 min at 1200 g to obtain plasma; the remainder was used directly in the whole blood assay.
Reporter mycobacteria. M. bovis BCG, Montreal strain, was transformed with the shuttle plasmid pSMT1, as described elsewhere [26] . pSMT1 carries the luxAB genes from Vibrio harveyi, under the control of the mycobacterial GroEL (hsp60) promoter. The promoter is constitutively active, showing little or no response to stress in the plasmid construct [27] . Recombinant mycobacteria (BCG lux) were grown into the logarithmic phase in Middlebrook 7H9 culture medium with 10% ADC supplement (Becton Dickinson, Oxford, UK) and hygromycin (50 mg/mL; Roche, Lewes, UK). The culture was dispensed into vials; glycerol was added, to a final concentration of 25%; and the vials were frozen at Ϫ70ЊC. By plating an aliquot on Middlebrook 7H11 agar containing OADC supplement (Becton Dickinson), hygromycin (50 mg/mL), and amphotericin B (50 mg/mL; E. R. Squibb & Sons Ltd., Leatherhead, UK), each vial (2 mL) was shown to contain viable 7 3 ϫ 10 mycobacteria. Prior to each experiment, a vial was defrosted, added to 10 mL of 7H9/ADC/hygromycin medium, and incubated, with shaking, at 37ЊC for 72 hours. Mycobacteria were then centrifuged for 10 min at 2000 g, washed 3 times with sterile PBS, and suspended in 10 mL of sterile PBS. Luminescence was measured in serial 10-fold dilutions over a 20 s period, after injection of 0.1 mL of substrate (1% n-decyl aldehyde; Sigma) into a total volume of 1 mL in PBS in a tube luminometer (Berthold AutoLumat LB953). Results were expressed as relative light units (RLUs). A reading of 10 RLU was found to correspond to 1 cfu. The bacteria were then diluted with PBS to obtain a concentration of RLU/ 6 1 ϫ 10 mL prior to inoculation.
Whole blood assays. Aliquots of diluted whole blood (0.9 mL), prepared as described above, were inoculated with 0.1 mL of BCG lux, to obtain a final concentration of RLU/ml, in 7-mL 5 1 ϫ 10 screw-top, endotoxin-free Bijou tubes (Scientific Laboratory Supplies, Nottingham, UK), and were incubated at 37ЊC on a platform shaker (model STR6; Stuart Scientific, Stone, UK) set at 20 rev/ min. Triplicate samples were analyzed for mycobacterial viability at the time of inoculation and at time points up to 96 h. Parallel infection experiments were set up, using plasma samples from the same donor, and were processed in the same way as the whole blood assays.
At each time point, Bijou tubes were centrifuged for 10 min at 2000 g. Supernatant (0.4 mL) was aspirated from each tube and was immediately frozen at Ϫ70ЊC for subsequent cytokine measurements. RPMI (0.4 mL) was then added to each tube, and the contents were mixed and transferred into 20-mL Universal containers (SLS). Red blood cells were lysed by the addition of 8 mL of distilled water and incubated at room temperature for 10 min. Bijou tubes were rinsed with a further 2 mL of distilled water to remove any residual material, which was then added to the corresponding Universal container. After lysis, the samples were centrifuged at 2000 g for 10 min, the supernatant was discarded, and the remaining pellet of bacteria and cells was resuspended in 1 mL of PBS. Serial dilutions (10 Ϫ1 and 10 Ϫ2 ) were prepared, and luminescence was measured, as described above. Readings were carried out in duplicates for each individual tube and were expressed as the mean of triplicate samples. Where appropriate, 0.1-mL aliquots of serial dilutions were tested for colony-forming units, as described above.
Cytokine assays. Supernatants for cytokine assays were thawed, and serial dilutions were prepared in PBS/10% fetal calf serum (Life Technologies). IFN-g, TNF-a, and IL-10 were measured by ELISA, using antibody pairs, provided by BD PharMingen (Becton-Dickinson, Oxford, UK), according to the manufacturer's recommended protocols. Standard curves were generated, using reference cytokines provided by BD PharMingen. For each of the cytokines, the detection limit was 50 pg, and a linear response was observed for amounts up to 5000 pg. Results are expressed as the mean of duplicate readings for each sample, all of which were assayed in triplicate. For cytokine inhibition assays, monoclonal antibodies (MAbs) against TNFa (5 mg/mL), IFN-g (17.5 mg/mL), and IL-12 (10 mg/mL; all from R&D Systems Europe Ltd., Abingdon, UK) and against IFN-g receptor (2.5 mg/mL; Genzyme Diagnostics, Cambridge, MA), as well as isotype controls (goat IgG for anti-TNF-a and anti-IFNg and mouse IgG 1 for anti-IFN-g receptor and anti-IL-12, in the same concentrations as neutralizing antibodies), were added to aliquots of blood from tuberculin-positive individuals prior to inoculation with BCG lux, following the manufacturer's recommendations. At the concentrations used, each of the neutralizing antibodies was shown, by ELISA, to completely block detection of the target cytokine.
Statistical methods. Nonparametric statistical tests were used to avoid assumption of normally distributed data sets. To deter- A, Growth in mycobacterial culture medium: 10 4 RLU (10 3 cfu) of BCG lux was inoculated into 7H9 mycobacterial culture medium, and the number of mycobacteria was measured over 18 days. At each time point, 100 mL was removed from the culture, and RLUs and colony-forming units were assessed in triplicate samples. B, Growth in whole blood: 10 5 RLU (10 4 cfu) of BCG lux was inoculated into triplicate samples of whole blood of a tuberculin-positive individual, and mycobacterial numbers were measured over 96 h. At each time point, the RLUs and colonyforming units were assessed in triplicate samples, following the described method. The means of the triplicate samples are shown alongside the error bars, which represent SDs. mine whether 2 sets of paired data were significantly different for a given variable, the Wilcoxon matched pairs signed-rank tests were used. All data were analyzed by using Stata statistics/data analysis (Stata Corp., College Station, TX).
Results

Reporter mycobacteria in a whole blood infection model.
To validate the use of bioluminescence to monitor the growth of mycobacteria during interaction with immune cells in whole blood, we inoculated aliquots of fresh, anticoagulated blood from volunteers with 10 5 RLU/mL of luciferase-labeled BCG (BCG lux). Figure 1 illustrates the growth of BCG lux, as measured by RLUs and colony-forming units, in bacterial culture medium ( figure 1A ) and in whole blood of a tuberculin-positive donor ( figure 1B) . In a series of initial experiments, we observed a similar pattern of growth, assessed by colony-forming units or RLUs. A reading of 10 RLU was found to correspond to ∼1 cfu (Spearman's correlation coefficient, ; ). The r p 1 P p .0001 more rapid and technically simpler luminescence assay was adopted for subsequent analysis of multiple samples from a panel of 20 volunteers.
Growth in whole blood and plasma.
To determine whether the cellular component of human blood affected mycobacterial viability, growth of BCG lux in whole blood was compared with growth in plasma samples from which blood cells had been removed by centrifugation prior to NOTE. Cytokine concentrations were measured during growth of BCG lux in whole blood of 10 tuberculin-positive and 10 tuberculin-negative individuals. Peak TNF-a and IL-10 concentrations were measured at 72 h and peak IFN-g concentration at 96 h. Medians and ranges are based on triplicate samples. Concentrations of IFN-g and TNF-a were significantly higher in plasma of tuberculinpositive individuals than in plasma of tuberculin-negative individuals (P p .005 by Wilcoxon signed-rank test).
infection. Figure 2 shows a representative experiment, comparing growth of BCG lux in whole blood ( figure 2A ) and plasma from a tuberculin-positive and a tuberculin-negative individual (figure 2B). For each individual, mycobacterial growth in whole blood was lower than that in plasma, which suggests that the presence of cellular elements was limiting the growth of the mycobacteria.
Mycobacterial growth in whole blood of tuberculin-positive and tuberculin-negative individuals.
To test whether mycobacterial viability in whole blood was influenced by immune status, the growth of BCG lux was compared in whole blood of tuberculinpositive and tuberculin-negative individuals. In all of the experiments in which paired samples were studied, less growth was observed in the whole blood of tuberculin-positive than in that of tuberculin-negative individuals. The combined results from all 20 individuals are shown in figure 3 , expressed as a growth ratio based on the following formula:
At 96 h, the growth of BCG lux was significantly lower in blood from tuberculin-positive individuals (median, 1.8; range, 0.3-6) than in blood from tuberculin-negative individuals (median, 4.9; range, 2.2-10;
, Wilcoxon signed-P p .005 rank test). In contrast, no difference in growth was detected in the plasma samples from the 2 groups ( ; data not P p .54 shown).
Associated cytokine production. Because IFN-g and TNFa have been shown to be critical for inhibiting mycobacterial growth in mice, we studied the production of IFN-g, TNF-a, and IL-10 during growth of BCG lux in whole blood. The time course for production of each of these cytokines was determined over the duration of the experiment. Peak levels of TNF-a and IL-10 were observed at 72 h, whereas IFN-g peaked at 96 h. The results for the panel of 20 volunteers, based on cytokine measurements at the peak time of production, are summarized in table 1.
Significantly more IFN-g and TNF-a were produced during growth of BCG lux in the blood of tuberculin-positive individuals than in the blood of tuberculin-negative individuals ( for both). There was no significant difference in the P p .005 amount of IL-10 produced ( ). P p .65 To evaluate the relationship between mycobacterial growth and cytokine production, we separated subjects into those showing restricted growth of BCG lux (defined as a growth ratio below the median of 1.8 for tuberculin-positive individuals [ ]) and those whose blood supported mycobacterial n p 6 growth (a growth ratio above the median [ ]). Subjects n p 14 with restricted growth produced significantly more TNF-a than those with unrestricted growth produced (median, 734 vs. 144 pg/mL, respectively;
). The production of IFN-g was P p .02 also significantly higher in the group with restricted growth (median, 329 vs. 18 pg/mL, respectively; ), whereas no P p .011 significant differences were seen in the production of IL-10 (median, 254 vs. 243 pg/mL; ). P p .5 Effect of neutralizing cytokines. To assess whether the differences in cytokine production between tuberculin-positive and tuberculin-negative individuals were responsible for the observed differences in growth of BCG lux, neutralizing antibodies were used to modulate the activity of key cytokines.
MAbs against TNF-a, IFN-g, IL-12, IFN-g receptor, and their isotype controls were added to aliquots of blood from tuberculin-positive individuals prior to inoculation with RLU/mL of BCG lux. Control samples from the same of the neutralizing MAbs was associated with a partial enhancement of mycobacterial growth. Addition of anti-TNF-a antibody increased mycobacterial growth in blood from only one of 5 tuberculin-positive individuals. Anti-IFN-g induced a 24% increase in mycobacterial growth; addition of antibody to IFN-g receptor resulted in a 26% increase in growth, and antibody to IL-12 resulted in a 33% increase in growth of BCG lux, compared with the controls. The presence of isotype controls did not alter growth of BCG lux.
Discussion
The vast majority of individuals exposed to infection with M. tuberculosis mount an immune response that prevents progression to primary disease. However, ∼10% of infected individuals go on to develop disease either following initial infection or at a later stage in life [28] . It is currently impossible to determine whether disease results from a poor initial response to infection or from a subsequent impairment of an initially protective response. The inability to distinguish individuals with lifelong immunity from those who are at risk of progressive disease presents a fundamental obstacle to the design of tuberculosis control strategies and to the rational development of improved vaccines.
Recognizing that tuberculin skin test reactivity does not provide a reliable indicator of protective immunity, many investigators have tried to identify individual cellular components, reactivity to specific antigens, or patterns of cytokine expression that might be associated with protective immune responses [23] .
Previous attempts to use mycobacterial viability as a means of assessing immunity in humans have focused on use of isolated cell fractions. Cheng et al. [29] assessed mycobacterial growth in peripheral blood-derived human monocytes obtained from individuals before and after BCG vaccination. Boney et al. [30] similarly used blood-derived monocytes to assess the effects of addition of a variety of cytokines and used a luciferase reporter system to monitor effects on mycobacterial viability. Silver et al. [31] described a cell culture model involving addition of T cells to infected macrophages. Whereas the combined action of macrophages and T cells was required for restriction of mycobacterial growth, the model did not differentiate between tuberculin-positive and tuberculin-negative individuals.
An important feature of the whole blood model described in the present study is that, in contrast to these earlier assays, changes in mycobacterial viability have been found to correlate with differences in immune status, as measured by tuberculin reactivity. The ability to distinguish individuals with a previously primed immune response to mycobacteria from an unexposed control group suggests that mycobacterial viability in the assay is determined by the presence of an antigen-specific acquired immune response.
Consistent with this interpretation are (1) the relationship between IFN-g and TNF-a production and mycobacterial growth and (2) the observed increase in mycobacterial growth following neutralization of IFN-g and IL-12. The correlation between viability and cytokine production is consistent with a central role for the IFN-g pathway in the antimycobacterial response, but it does not exclude a possible contribution by other effector mechanisms. As with other studies of immune parameters in human populations, overlaps between results in the different study groups can be observed. Larger studies using the whole blood model and involving healthy as well as diseased individuals might help to reduce such heterogeneity. The establishment of a model system in which the readout of mycobacterial viability reflects differences in acquired immune status has exciting potential for further studies of cellular and molecular mechanisms involved in control of mycobacterial growth.
The experiments described in the present study have focused on use of BCG lux as a reporter. Whereas this system has obvious practical advantages over the use of M. tuberculosis itself in relation to safety, it is possible that different mechanisms are required for control of the virulent and attenuated strains. Preliminary studies with M. tuberculosis lux have shown a pattern of growth in the blood of tuberculin-positive and tuberculin-negative individuals similar to that seen with BCG lux (authors' unpublished observations), but further detailed studies in the whole blood model will be required to establish whether growth of the 2 bacteria is controlled in the same way.
Constructs in which luciferase expression is placed under the control of promoters that are differentially regulated during the course of the infection represent a possible approach to further enhancement of the discriminatory ability of the whole blood assay.
Although it could be argued that whole blood is not the ideal system for studying mycobacterial immunity, lymphohematogenous spread occurs during early dissemination of mycobacteria [32] , and bacteremia is increasingly recognized, particularly in the immunocompromised [33] . The use of whole blood in a functional assay that assesses mycobacterial growth as the final effector function is, therefore, a relevant model for understanding key elements of protective immunity.
Current research efforts toward the development of a more effective vaccine for the prevention of tuberculosis are driven by the availability of the genome sequence for M. tuberculosis [34] . Screening of the resulting panel of subunit and live-attenuated candidates currently relies on extensive testing in mouse and guinea pig models, which may only partially reflect vaccine activity in humans. Once identified, promising candidates will have to undergo long and expensive prospective clinical trials to determine their protetctive efficacy in human populations. A human in vitro assay able to detect potential protective responses elicited by a vaccine candidate in preliminary immunogenicity trials would be of great benefit for rational vaccine development. In this context, the whole blood assay might provide an important new tool.
